Jazz Pharmaceuticals completed the acquisition of Actio Biosciences for $820 million upfront to add ABS-1230. This precise, oral small-molecule aims to treat all KCNT1-related epilepsy patients, enhancing Jazz's rare disease portfolio.
Jazz Pharmaceuticals completed the acquisition of Actio Biosciences for $820 million upfront to add ABS-1230. This precise, oral small-molecule aims to treat all KCNT1-related epilepsy patients, enhancing Jazz's rare disease portfolio.